Option chain shows key data for Korro Bio's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Korro Bio.

Korro Bio (NASDAQ:KRRO) Stock, Option Chain

Korro Bio

Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.

Stock market analysts

News

Initiation

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

ALAB

ENGN

INGM

KRRO

This TechnipFMC Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Newark,,Nj,-15,Sep,2017-,Planes,From,United,Airlines,(ua)

Intraday Update

Movers

AMPS

ASPN

OKLO

United Airlines Posts Upbeat Earnings, Joins Morgan Stanley, U.S. Bancorp And Other Big Stocks Moving Higher On Wednesday

Biotech

Earnings

Large Cap

Health Care

Price Target

Offerings

Small Cap

Federal Reserve

Tech

General

ASML

AVGO

IFNNF

U.S. stocks reacted positively following the Federal Open Market Committee&#39;s announcement in mid-September that it would lower interest rates by 50 basis points, wider than many analysts had anticipated.

3 Stocks That Could Rise on European Bank Interest Rate Cuts

Korro Bio Inc


<p><strong>POSaBIT Systems Corporation </strong>(OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/POSAF#OTCQX">POSAF</a>), a provider of payments and point-of-sale infrastructure for the cannabis industry, has integrated Metrc Connect reporting in its point-of-sale system for all states that utilize the track and trace system. Metrc, a U.S.-based provider of cannabis regulatory technology systems, combines software, radio-frequency identification (RFID), customer support, and a secure database to track cannabis from growth, harvest, and processing to testing and transport.</p>
<p>"We are excited that POSaBIT has achieved full integration with Metrc Connect across all States, including Oregon," stated <strong>Michael Johnson,</strong> CEO of Metrc. "POSaBIT's commitment to adopt Metrc Connect highlights their dedication to providing a smooth transition and optimal experience for their customers."</p>
<p>All POSaBIT partner dispensaries in Metrc regions now report necessary data to their regulatory bodies through the company's point-of-sale software.</p>
<p><strong>Read Also: </strong><a href="https://www.benzinga.com/general/market-summary/24/11/42100955/the-u-s-cannabis-strategy-no-ones-talking-about-inside-canopys-300m-plan">The U.S. Cannabis Strategy No One&#8217;s Talking About: Inside Canopy&#8217;s $300M Plan</a></p>
<p><em><strong>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.</strong></em></p>
<p><strong>Ryan Hamlin</strong>, CEO/co-founder of POSaBIT, commented, "We have partnered closely with Metrc over the years and we appreciate their industry leadership when it comes to compliance. This continued focus on compliance and regulatory requirements by POSaBIT has proven to be one of the main reasons so many merchants have migrated over from older legacy Point of Sale providers to a more innovative POSaBIT POS solution."</p>
<p>Earlier this month, Metrc <a href="https://www.benzinga.com/markets/cannabis/24/11/41689697/metrc-to-support-virginias-regulation-of-medical-marijuana-market-signs-new-track-and-trace-gove">signed a contract</a> with the Commonwealth of Virginia to support the regulation of its medical cannabis market. Metrc&#8217;s track-and-trace platform provides transparency to ensure regulatory compliance, help combat the illicit market and safeguard the health and well-being of Virginia&#8217;s patients. The Metrc system allows licensed operators to track activities affecting a plant&#8217;s status or the creation of cannabis-based products, including origin, testing results, handling, and chain-of-custody information via the company's RFID tracking model and software-as-a-service (SaaS) system. The information is then easily accessible to state regulators.</p>
<p>Metrc is engaged in 27 government contracts and serves more than 500,000 users, including growers, testing facilities, dispensaries, state regulators and law enforcement officials.</p>
<p><strong>Price Action </strong></p>
<p><strong>POSaBit shares closed Wednesday&#8217;s market session flat at $0.081 per share. </strong></p>
<p><strong>Read Next:</strong></p>
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/06/39293215/metrc-enters-track-and-trace-cannabis-contract-with-a-tribal-government-via-partnership-with-cal"><strong>Metrc Enters Track-And-Trace Cannabis Contract With A Tribal Government Via Partnership With California Native American Tribe</strong></a></li>
<li></li>
</ul>
<p><em>Photo: Courtesy of Plateresca via Shutterstock</em></p>


Cannabis

POSAF

Cannabis Fintech POSaBIT Integrates Metrc Connect Reporting

<p>Citigroup  analyst Keith Horowitz   maintains Goldman Sachs Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) with a Neutral and raises the price target from $485 to $585.</p>


Citigroup Maintains Neutral on Goldman Sachs Gr, Raises Price Target to $585

WIIM

The S&P and Nasdaq are lower as Nvidia falls after its quarterly earnings report.

CATX

Perspective Therapeutics shares are trading lower. The company announced initial results from its ongoing Phase 1/2a clinical trial of [212Pb]VMT-α-NET.

<p>RBC Capital  analyst Matthew Hedberg   maintains Snowflake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) with a Outperform and raises the price target from $175 to $188.</p>


SNOW

RBC Capital Maintains Outperform on Snowflake, Raises Price Target to $188

<p>Lake Street  analyst Eric Martinuzzi   maintains Universal Technical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UTI#NYSE">UTI</a>) with a Buy and raises the price target from $19 to $22.</p>


Lake Street Maintains Buy on Universal Technical, Raises Price Target to $22

<p>B of A Securities  analyst Bradley Sills   maintains Snowflake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) with a Neutral and raises the price target from $160 to $185.</p>


B of A Securities Maintains Neutral on Snowflake, Raises Price Target to $185

NOEMU

Trading Halt: Halt status updated at 10:35:00 AM ET: Quotation Resumption: IPO Security - Released for Quotation

DYNXU

<p>The Alabama Court of Civil Appeals rejected the Alabama Medical Cannabis Commission's (AMCC) attempt to dismiss a lawsuit filed by a medical marijuana operator, challenging its already troubled medical cannabis licensing process.</p>
<h3 class="wp-block-heading">What Happened</h3>
<p>Jemmstone Alabama, LLC, filed the lawsuit in December 2023, alleging mismanagement and improper denial of its application for an integrated medical cannabis facility license, <a href="https://www.alreporter.com/2024/11/18/court-rejects-amccs-bid-to-dismiss-lawsuit-medical-cannabis-in-limbo/">reported</a> Alabama Political Reporter.</p>
<p>In the lawsuit, Jemmstone initially named AMCC only as a defendant, in the caption of the complaint. However, throughout the document, the plaintiff consistently referenced individual commissioners.</p>
<p>The AMCC sought to take advantage of this procedural&nbsp;detail, insisting the absence of commissioners from the caption made the complaint invalid under the Alabama Rules of Civil Procedure.</p>
<p>The commission argued that the lawsuit should be dismissed on jurisdictional grounds, claiming sovereign immunity.</p>
<p><strong>Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/07/39989148/real-life-american-hero-and-veteran-cant-get-his-medicine-as-alabama-medical-cannabis-legal-saga">‘Real-Life American Hero' And Veteran Can't Get His Medicine As Alabama Medical Cannabis Legal Saga Continues, Activists Say Enough Already</a></strong></p>
<p>The appellate court ruled that the omission of commissioners&#8217; names from the caption was a technical error, rejecting AMCC's claim of sovereign immunity and allowing the lawsuit to proceed.</p>
<p>The court also rejected the AMCC&#8217;s claim that improper service of process made the case invalid.</p>
<ul>
<li><strong><em>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.</em></strong></li>
</ul>
<h3 class="wp-block-heading">What's Next</h3>
<p>The case now proceeds in the Montgomery Circuit Court.</p>
<p>The medical marijuana program was legalized in 2021 in Alabama. However, its implementation has been postponed due to ongoing legal challenges.</p>
<p>So far, AMCC managed to award, but not issue licenses to businesses that have applied to enter the state's medical market.</p>
<p>In December 2023, the Alabama cannabis regulator awarded 20 medical cannabis licenses for the production, distribution, dispensing and testing of medical marijuana (MMJ) as well as five of the most coveted permits – the integrated facility licenses, which allow for vertical integration. This move came after several failed attempts to allocate licenses.</p>
<p>Read Next:</p>
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/09/40735369/new-hope-for-alabama-medical-marijuana-program-as-judge-considers-revising-licensing-restriction"><strong>New Hope For Alabama Medical Marijuana Program As Judge Considers Revising Licensing Restrictions</strong></a></li>
</ul>


Legal

Alabama Lawsuit Against Cannabis Regulator Over Medical Marijuana Licensing Moves Forward

<p>RBC Capital  analyst Sean Dodge   reiterates Sotera Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHC#NASDAQ">SHC</a>) with a Outperform and maintains $17 price target.</p>


Reiteration

RBC Capital Reiterates Outperform on Sotera Health, Maintains $17 Price Target

<p>B of A Securities  analyst Tal Liani   maintains Palo Alto Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>) with a Neutral and raises the price target from $400 to $430.</p>


PANW

B of A Securities Maintains Neutral on Palo Alto Networks, Raises Price Target to $430

Macro Economic Events

Econ #s

Economics

USA Natural Gas Storage -3B Vs 2B Est.; 42B Prior

<p><a href="https://thebearcave.substack.com/p/problems-at-transdigm-tdg" title="https://thebearcave.substack.com/p/problems-at-transdigm-tdg">https://thebearcave.substack.com/p/problems-at-transdigm-tdg</a></p>


Short Sellers

Watching TransDigm; The Bear Cave Research Issues Report Titled "Problems at TransDigm"

<p>Deep-pocketed investors have adopted a bearish approach towards ConocoPhillips (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COP#NYSE">COP</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in COP usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 8 extraordinary options activities for ConocoPhillips. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 37% leaning bullish and 62% bearish. Among these notable options, 2 are puts, totaling $60,600, and 6 are calls, amounting to $730,955.</p>
<h3>Projected Price Targets</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $115.0 to $135.0 for ConocoPhillips over the recent three months. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in ConocoPhillips's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to ConocoPhillips's substantial trades, within a strike price spectrum from $115.0 to $135.0 over the preceding 30 days.</p>
<h3>ConocoPhillips Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732203127_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>COP</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$3.05</td>
<td>$3.0</td>
<td>$3.0</td>
<td>$130.00</td>
<td>$450.0K</td>
<td align="right">61</td>
<td>1.8K</td>
</tr>
<tr>
<td>COP</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$3.05</td>
<td>$3.0</td>
<td>$3.0</td>
<td>$130.00</td>
<td>$116.1K</td>
<td align="right">61</td>
<td>2.2K</td>
</tr>
<tr>
<td>COP</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$3.05</td>
<td>$3.0</td>
<td>$3.0</td>
<td>$130.00</td>
<td>$59.4K</td>
<td align="right">61</td>
<td>375</td>
</tr>
<tr>
<td>COP</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$3.0</td>
<td>$2.99</td>
<td>$3.0</td>
<td>$130.00</td>
<td>$47.1K</td>
<td align="right">61</td>
<td>2.4K</td>
</tr>
<tr>
<td>COP</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$7.4</td>
<td>$7.05</td>
<td>$7.4</td>
<td>$115.00</td>
<td>$34.0K</td>
<td align="right">208</td>
<td>46</td>
</tr>
</tbody>
</table>
</p>
<h3>About ConocoPhillips</h3>
<p>ConocoPhillips is a US-based independent exploration and production firm. In 2023, it produced 1.2 million barrels per day of oil and natural gas liquids and 3.1 billion cubic feet per day of natural gas, primarily from Alaska and the Lower 48 in the United States and Norway in Europe and several countries in Asia-Pacific and the Middle East. Proven reserves at year-end 2023 were 6.8 billion barrels of oil equivalent.</p>
<h3>Present Market Standing of ConocoPhillips</h3>
<ul>
<li>Currently trading with a volume of 705,190, the COP's price is up by 1.46%, now at $115.09. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 77 days.</li>
</ul>
<h3>What Analysts Are Saying About ConocoPhillips</h3>
<p>3 market experts have recently issued ratings for this stock, with a consensus target price of $139.0.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Maintaining their stance, an analyst from Mizuho continues to hold a Neutral rating for ConocoPhillips, targeting a price of $132.<br />
&#x2A; An analyst from Susquehanna has decided to maintain their Positive rating on ConocoPhillips, which currently sits at a price target of $148.<br />
&#x2A; Consistent in their evaluation, an analyst from Barclays keeps a Overweight rating on ConocoPhillips with a target price of $137. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest ConocoPhillips options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


Options

Looking At ConocoPhillips's Recent Unusual Options Activity

<p>Investors with a lot of money to spend have taken a bearish stance on <strong>Iris Energy</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IREN#NASDAQ">IREN</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with IREN, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 17 uncommon options trades for Iris Energy.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 41% bullish and 52%, bearish.</p>
<p>Out of all of the special options we uncovered, 4 are puts, for a total amount of $817,500, and 13 are calls, for a total amount of $738,926.</p>
<h3>Projected Price Targets</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $6.0 to $18.0 for Iris Energy over the recent three months. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Iris Energy's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Iris Energy's significant trades, within a strike price range of $6.0 to $18.0, over the past month.</p>
<h3>Iris Energy Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732203121_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>IREN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$1.6</td>
<td>$1.55</td>
<td>$1.6</td>
<td>$9.00</td>
<td>$320.0K</td>
<td>5.4K</td>
<td>4.0K</td>
</tr>
<tr>
<td>IREN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$1.65</td>
<td>$1.55</td>
<td>$1.55</td>
<td>$9.00</td>
<td>$310.2K</td>
<td>5.4K</td>
<td>2.0K</td>
</tr>
<tr>
<td>IREN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$1.65</td>
<td>$1.6</td>
<td>$1.6</td>
<td>$9.00</td>
<td>$160.0K</td>
<td>5.4K</td>
<td>5.0K</td>
</tr>
<tr>
<td>IREN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$1.55</td>
<td>$1.45</td>
<td>$1.5</td>
<td>$18.00</td>
<td>$150.1K</td>
<td>8.9K</td>
<td>2.0K</td>
</tr>
<tr>
<td>IREN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$4.3</td>
<td>$4.1</td>
<td>$4.1</td>
<td>$8.00</td>
<td>$120.5K</td>
<td>2.2K</td>
<td>295</td>
</tr>
</tbody>
</table>
</p>
<h3>About Iris Energy</h3>
<p>Iris Energy Ltd is a Bitcoin mining company. It builds, owns, and operates data centers and electrical infrastructure for the mining of Bitcoin powered by renewable energy. The company's mining operations generate revenue by earning Bitcoin through a combination of block rewards and transaction fees from the operation of its specialized computers called Application-specific Integrated Circuits and exchanging these Bitcoin for currencies such as USD or CAD on a daily basis.</p>
<p>Following our analysis of the options activities associated with Iris Energy, we pivot to a closer look at the company's own performance.</p>
<h3>Current Position of Iris Energy</h3>
<ul>
<li>Currently trading with a volume of 10,433,826, the IREN's price is down by -5.15%, now at $9.58. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 5 days.</li>
</ul>
<h3>Expert Opinions on Iris Energy</h3>
<p>1 market experts have recently issued ratings for this stock, with a consensus target price of $20.0.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; In a cautious move, an analyst from Cantor Fitzgerald downgraded its rating to Overweight, setting a price target of $20. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Iris Energy with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


IREN

Smart Money Is Betting Big In IREN Options

<p>Deep-pocketed investors have adopted a bearish approach towards Deere (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DE#NYSE">DE</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in DE usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 20 extraordinary options activities for Deere. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 35% leaning bullish and 45% bearish. Among these notable options, 16 are puts, totaling $779,083, and 4 are calls, amounting to $204,500.</p>
<h3>Expected Price Movements</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $380.0 and $460.0 for Deere, spanning the last three months.</p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Deere's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Deere's whale trades within a strike price range from $380.0 to $460.0 in the last 30 days. </p>
<h3>Deere 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732203115_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>DE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$16.8</td>
<td>$14.9</td>
<td>$16.8</td>
<td>$420.00</td>
<td>$100.8K</td>
<td>1.5K</td>
<td align="right">176</td>
</tr>
<tr>
<td>DE</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$17.0</td>
<td>$16.95</td>
<td>$17.0</td>
<td>$420.00</td>
<td>$85.0K</td>
<td>454</td>
<td align="right">260</td>
</tr>
<tr>
<td>DE</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$16.65</td>
<td>$13.55</td>
<td>$14.79</td>
<td>$420.00</td>
<td>$81.1K</td>
<td>454</td>
<td align="right">310</td>
</tr>
<tr>
<td>DE</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$18.75</td>
<td>$15.4</td>
<td>$18.75</td>
<td>$420.00</td>
<td>$65.6K</td>
<td>454</td>
<td align="right">85</td>
</tr>
<tr>
<td>DE</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$16.35</td>
<td>$14.45</td>
<td>$16.35</td>
<td>$430.00</td>
<td>$52.3K</td>
<td>112</td>
<td align="right">163</td>
</tr>
</tbody>
</table>
</p>
<h3>About Deere</h3>
<p>Deere is the world's leading manufacturer of agricultural equipment, producing some of the most recognizable machines in the heavy machinery industry in their green and yellow livery. The company is divided into four reportable segments: production and precision agriculture, small agriculture and turf, construction and forestry, and John Deere Capital. Its products are available through an extensive dealer network, which includes over 2,000 dealer locations in North America and approximately 3,700 locations globally. John Deere Capital provides retail financing for machinery to its customers, in addition to wholesale financing for dealers, which increases the likelihood of Deere product sales.</p>
<p>After a thorough review of the options trading surrounding Deere, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Present Market Standing of Deere</h3>
<ul>
<li>With a trading volume of 1,145,107, the price of DE is up by 5.35%, reaching $426.62.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 0 days from now.</li>
</ul>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.</p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Deere with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


This Is What Whales Are Betting On Deere

<p>Bringing Extensive Financial Expertise To Support Growth And Enhance Shareholder Value</p>


Management

UAVS

AgEagle Aerial Systems Appoints Adrienne Anderson As Interim CFO

Market Summary

$BTC

NVDA

Benzinga Market Summary: Nvidia Shares Fall After Earnings Report, Initial Jobless Claims Come In Below Estimates, Snowflake Stock Surges On Earnings Report, Bitcoin Rises Above $98,000

<p><a href="https://grizzlyreports.com/we-believe-sharkninja-inc-nyse-sn-is-a-china-hustle-based-on-rampant-looting-and-conflicts-of-interest-with-the-chinese-chairman/" title="https://grizzlyreports.com/we-believe-sharkninja-inc-nyse-sn-is-a-china-hustle-based-on-rampant-looting-and-conflicts-of-interest-with-the-chinese-chairman/">https://grizzlyreports.com/we-believe-sharkninja-inc-nyse-sn-is-a-china-hustle-based-on-rampant-looting-and-conflicts-of-interest-with-the-chinese-chairman/</a></p>


Watching Shares Of SharkNinja; Grizzly Research Issues Report On The Co. Titled, "We Believe SharkNinja, Inc is a China Hustle Based on Rampant Looting and Conflicts of Interest with the Chinese Chairman"

RBC Capital raised the firm's price target on Korro Bio (KRRO) to $105 from $95 and keeps an Outperform rating on the shares. The firm notes that R...

Korro Bio price target raised to $105 from $95 at RBC Capital

H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating on Korro Bio (KRRO – Research Report) today and set a price target of $115.00. Mitc...

Korro Bio's Promising Regulatory and Preclinical Advances Earn a Buy Rating from Analyst Mitchell Kapoor

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Korro Bio (KRRO – Research Report), Paragon 28 (FNA ...

Analysts' Top Healthcare Picks: Korro Bio (KRRO), Paragon 28 (FNA)

Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on Korro Bio (KRRO – Research Report) today and set a price target of $180.00. The com...

Piper Sandler Reaffirms Their Buy Rating on Korro Bio (KRRO)

Korro Bio GAAP EPS of -$2.26

Korro Bio, Inc. ( ($KRRO) ) has released its Q3 earnings. Here is a breakdown of the information Korro Bio, Inc. presented to its investors. Korro ...

Korro Bio's Progress and Financial Updates

JonesResearch analyst Catherine Novack initiated coverage of Korro Bio (KRRO) with a Buy rating and $130 price target Korro is one of a growing num...

Korro Bio initiated with a Buy at JonesResearch

Catherine Novack, an analyst from JonesTrading, has initiated a new Buy rating on Korro Bio (KRRO). Catherine Novack has given her Buy rating due t...

Korro Bio: Buy Rating Backed by Innovative RNA Editing Focus and Strategic Partnerships

Korro Bio (KRRO) announced that it has received approval from the Australian Bellberry Human Research Ethics Committee, HREC, and clearance from th...

Korro Bio receives HREC approval, CTN clearance to initiate Phase 1/2a study

Korro gets Australian HREC approval to initiate phase 1/2a study for antitrypsin deficiency

AMGN

Press Releases

Korro Reports Second Quarter 2024 Financial Results and Provides Business Updates

Korro to Participate in Upcoming September Investor and Scientific Conferences

Korro Announces Addition of Industry Veteran Katharine Knobil to and Resignation of David Lucchino From Its Board of Directors

Korro to Participate in Upcoming Investor Conferences

Korro Bio Announces Collaboration with Novo Nordisk to Develop Two Therapeutic Candidates

Korro Announces Oral and Poster Presentations at the 20th Annual Meeting of the Oligonucleotide Therapeutics Society

Korro Announces Regulatory Filing for Initiation of KRRO-110 First-In-Human Study and Formation of Clinical Advisory Board

Korro Reports Third Quarter 2024 Financial Results and Provides Business Updates

Korro to Present at the Jefferies London Healthcare Conference

Korro Receives Australian HREC Approval and CTN Clearance to Initiate Phase 1/2a Clinical Study (REWRITE) of KRRO-110 for Alpha-1 Antitrypsin Deficiency

Comments

Korro Bio

Korro Bio (KRRO) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga